Results 281 to 290 of about 74,509 (297)
Some of the next articles are maybe not open access.
The pharmacogenomics of epilepsy
Expert Review of Neurotherapeutics, 2015Genetic factors contribute to the high interindividual variability in response to antiepileptic drugs. However, most genetic markers identified to date have limited sensitivity and specificity, and the value of genetic testing in guiding antiepileptic drug (AED) therapy is limited.
FRANCO, VALENTINA, PERUCCA, EMILIO
openaire +4 more sources
Pharmacogenomics, 2004
It is well known that genetic polymorphisms, such as SNPs, vary between races so that not only Western populations' pharmacogenetic/pharmacogenomic data but also data from Asians are viewed as vital to drug development and clinical practice. For this report, the current state of pharmacogenetic/pharmacogenomic-related activities in five Asian countries
Hiroshi Gushima +2 more
openaire +3 more sources
It is well known that genetic polymorphisms, such as SNPs, vary between races so that not only Western populations' pharmacogenetic/pharmacogenomic data but also data from Asians are viewed as vital to drug development and clinical practice. For this report, the current state of pharmacogenetic/pharmacogenomic-related activities in five Asian countries
Hiroshi Gushima +2 more
openaire +3 more sources
Pharmacogenomics and schizophrenia
European Journal of Pharmacology, 2000Although antipsychotic drugs are effective in alleviating schizophrenic symptoms, individual differences in patient response suggest that genetic components play a major role, and pharmacogenetic studies have indicated the possibility for a more individually based pharmacotherapy. The new field of pharmacogenomics, which focuses on genetic determinants
Hirokazu Tachikawa +2 more
openaire +3 more sources
Pharmacogenomics of Cyclooxygenases
Pharmacogenomics, 2015Cyclooxygenases (COX-1 and COX-2) are key enzymes in several physiopathological processes. Many adverse drugs reactions to NSAIDs are attributable to COX-inhibition. The genes coding for these enzymes (PTGS1 and PTGS2) are highly variable, and variations in these genes may underlie the risk of developing, or the clinical evolution of, several diseases ...
José A. G. Agúndez +3 more
openaire +3 more sources
Pharmacogenomics in Anesthesia
Anesthesiology Clinics, 2017A significant number of commonly administered medications in anesthesia show wide clinical interpatient variability. Some of these include neuromuscular blockers, opioids, local anesthetics, and inhalation anesthetics. Individual genetic makeup may account for and predict cardiovascular outcomes after cardiac surgery. These interactions can manifest at
Ramsey Saba +2 more
openaire +2 more sources
Current Pharmaceutical Design, 2006
Patient response to asthma therapy is consistently observed to be heterogeneous. Pharmacogenomics is the study of inherited differences in interindividual drug disposition and effects, with the goal of selecting the optimal drug therapy and dosage for each patient.
Ewald Benediktus +2 more
openaire +3 more sources
Patient response to asthma therapy is consistently observed to be heterogeneous. Pharmacogenomics is the study of inherited differences in interindividual drug disposition and effects, with the goal of selecting the optimal drug therapy and dosage for each patient.
Ewald Benediktus +2 more
openaire +3 more sources
Microarrays in Pharmacogenomics
Journal of Biopharmaceutical Statistics, 2004DNA array technology provides tools for studying the expression profiles of a large number of distinct genes simultaneously.
openaire +2 more sources
The pharmacogenomics of osteosarcoma
The Pharmacogenomics Journal, 2016Osteosarcoma (OS), the most common malignant tumor of bone, is presently treated with multidrug neoadjuvant chemotherapy protocols, which allow to cure 60-65% of patients but also induce toxicity events that cannot be predicted or efficiently prevented.
Massimo Serra, Claudia Maria Hattinger
openaire +3 more sources
The Journal of Clinical Pharmacology, 2007
The human genome project and related research initiatives have enabled the identification of a significant number of genetic variants that are predictive of drug response and outcome (pharmacogenomic biomarkers). As yet, incorporation of routine pharmacogenomic testing into clinical practice has been relatively modest.
openaire +3 more sources
The human genome project and related research initiatives have enabled the identification of a significant number of genetic variants that are predictive of drug response and outcome (pharmacogenomic biomarkers). As yet, incorporation of routine pharmacogenomic testing into clinical practice has been relatively modest.
openaire +3 more sources
Pharmacogenomics of hypertension
Current Opinion in Nephrology and Hypertension, 2003The emerging field of pharmacogenomics has the potential to fundamentally change the management of essential hypertension, a common, perhaps polygenic syndrome characterized by substantial inter-individual variability in drug responsiveness. As understanding of sequence diversity in the human genome progresses, the prospect grows for tailoring the ...
Daniel T. O'Connor, Peter E. Cadman
openaire +2 more sources